News of Note—Boehringer expands China CDMO operation

news of note
(Pixabay)

> Germany's Boehringer Ingelheim is adding a bioreactor to its CDMO operation in China in anticipation of producing a monoclonal antibody at the facility this year. Release 

> The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is providing $32 million in grants for a long list of projects designed to improve biopharmaceutical manufacturing technology. Release

> MedPharm is investing $4 million to triple the size of its facility in Durham, North Carolina, for formulation development and performance testing of topical and transdermal medicines as well as increasing its LC/MS capacity and the automation of sample handling. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> The European Medicines Agency has reinstated the GMP manufacturing certificate to the Bristol Laboratories plant in Luton after a follow-up inspection found it had resolved issues raised in 2017. Report

Suggested Articles

As a key global ingredient supplier, problems in China can ripple worldwide as they have for Swiss CDMO Lonza.

What challenges continue to plague the pharmaceutical industry for almost a decade? Check out this remarkable innovation in glass science that may be the…

WuXi Biologics says its plant in Wuxi, China, has gotten the go-ahead from the FDA to make HIV drug Trogarzo for TaiMed Biologics.